Brief: Eloxx Pharmaceuticals Announces Fast Track Designation For Elx-02 For Treatment Of Cystic Fibrosis Patients With Nonsense Mutations
09/09/2021 14:27
Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION FOR
ELX-02 FOR TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH NONSENSE
MUTATIONS
* ELOXX PHARMACEUTICALS INC - EXPECTS TO PRESENT DATA FROM
FIRST
FOUR TREATMENT ARMS IN Q4 OF 2021
Source text for Eikon: ID:nGNX5hGkl0
Further company coverage: ELOX.O
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome